MTST Stock Overview
A precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MetaStat, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.003 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 11 Month Change | -96.67% |
| 3 Month Change | -50.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -99.60% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MTST | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 3.9% | 1.6% |
| 1Y | n/a | 4.7% | 32.3% |
Return vs Industry: Insufficient data to determine how MTST performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how MTST performed against the US Market.
Price Volatility
| MTST volatility | |
|---|---|
| MTST Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MTST's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MTST's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Douglas Hamilton | www.metastat.com |
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis.
MetaStat, Inc. Fundamentals Summary
| MTST fundamental statistics | |
|---|---|
| Market cap | US$587.00 |
| Earnings (TTM) | -US$3.31m |
| Revenue (TTM) | US$23.30k |
0.0x
P/S Ratio0.0x
P/E RatioIs MTST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTST income statement (TTM) | |
|---|---|
| Revenue | US$23.30k |
| Cost of Revenue | US$1.26m |
| Gross Profit | -US$1.23m |
| Other Expenses | US$2.08m |
| Earnings | -US$3.31m |
Last Reported Earnings
Feb 28, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MTST perform over the long term?
See historical performance and comparison